162 related articles for article (PubMed ID: 34736510)
21. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
22. Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related.
Bos R; van Diest PJ; van der Groep P; Shvarts A; Greijer AE; van der Wall E
Breast Cancer Res; 2004; 6(4):R450-9. PubMed ID: 15217513
[TBL] [Abstract][Full Text] [Related]
23. Alteration of REDD1-mediated mammalian target of rapamycin pathway and hypoxia-inducible factor-1α regulation in human breast cancer.
Koo JS; Jung W
Pathobiology; 2010; 77(6):289-300. PubMed ID: 21266827
[TBL] [Abstract][Full Text] [Related]
24. Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Breast Cancer Res; 2007; 9(6):R89. PubMed ID: 18096060
[TBL] [Abstract][Full Text] [Related]
25. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
[TBL] [Abstract][Full Text] [Related]
26. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Hughes KS; Schnaper LA; Bellon JR; Cirrincione CT; Berry DA; McCormick B; Muss HB; Smith BL; Hudis CA; Winer EP; Wood WC
J Clin Oncol; 2013 Jul; 31(19):2382-7. PubMed ID: 23690420
[TBL] [Abstract][Full Text] [Related]
27. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.
De Francesco EM; Sims AH; Maggiolini M; Sotgia F; Lisanti MP; Clarke RB
Breast Cancer Res; 2017 Dec; 19(1):129. PubMed ID: 29212519
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients.
Kaya AO; Gunel N; Benekli M; Akyurek N; Buyukberber S; Tatli H; Coskun U; Yildiz R; Yaman E; Ozturk B
J BUON; 2012; 17(4):663-8. PubMed ID: 23335522
[TBL] [Abstract][Full Text] [Related]
29. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
30. Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.
Koda M; Kanczuga-Koda L; Sulkowska M; Surmacz E; Sulkowski S
BMC Cancer; 2010 Jun; 10():320. PubMed ID: 20569445
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Gruber G; Greiner RH; Hlushchuk R; Aebersold DM; Altermatt HJ; Berclaz G; Djonov V
Breast Cancer Res; 2004; 6(3):R191-8. PubMed ID: 15084243
[TBL] [Abstract][Full Text] [Related]
32. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
[TBL] [Abstract][Full Text] [Related]
33. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
Schindl M; Schoppmann SF; Samonigg H; Hausmaninger H; Kwasny W; Gnant M; Jakesz R; Kubista E; Birner P; Oberhuber G;
Clin Cancer Res; 2002 Jun; 8(6):1831-7. PubMed ID: 12060624
[TBL] [Abstract][Full Text] [Related]
36. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
37. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs).
De Francesco EM; Lappano R; Santolla MF; Marsico S; Caruso A; Maggiolini M
Breast Cancer Res; 2013; 15(4):R64. PubMed ID: 23947803
[TBL] [Abstract][Full Text] [Related]
38. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
[TBL] [Abstract][Full Text] [Related]
39. Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.
Nalwoga H; Ahmed L; Arnes JB; Wabinga H; Akslen LA
PLoS One; 2016; 11(1):e0146823. PubMed ID: 26760782
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast cancer.
Schoppmann SF; Fenzl A; Schindl M; Bachleitner-Hofmann T; Nagy K; Gnant M; Horvat R; Jakesz R; Birner P
Breast Cancer Res Treat; 2006 Sep; 99(2):135-41. PubMed ID: 16555123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
